We joined Linda Mileshkin (Peter MacCallum Cancer Centre) following her presentation at ESMO 2019 to discuss the disparities of starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial.
1. Could you tell us a little about the OUTBACK trial and its findings? (0:06)
2. What was the impact of the delayed start of adjuvant therapy on clinical outcomes? (1:31)
3. What can be done to minimise these disparities? (2:01)
4. What are the key take home messages of your presentation? (2:40)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Linda Mileshkin has nothing to disclose in relation to this video.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Gynaecological Oncology
Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer
touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective […]
Julius Strauss, ESMO 2021: Long-term Follow-up of Patients with HPV–associated Malignancies Treated with Bintrafusp Alfa
touchONCOLOGY joins Dr Julius Strauss (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA), to discuss the long-term follow-up of patients with human papillomavirus–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. Questions 1. What are the unmet needs in the treatment of human papillomavirus (HPV)-associated cancers? (00:15-01:37) 2. […]
Shibani Nicum, ESMO 2021: First Results of the OCTOVA Trial
touchONCOLOGY joins Dr Shibani Nicum (University College London, UK) at ESMO 2021 to present the first results of the OCTOVA trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer. Questions 1. What are the unmet needs in the treatment of ovarian cancer patients who relapse within 12 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!